Wordt geladen...
The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8(+) T cell responses
Success in eliciting tumor rejection by therapeutic blockade of T cell checkpoint inhibitors, such as PD-1/PD-L1 and CTLA-4, has spurred re-evaluation of additional receptors that regulate antitumor responses. Here we summarize our recent studies characterizing the role of co-inhibitory receptor TIG...
Bewaard in:
| Gepubliceerd in: | Oncoimmunology |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570113/ https://ncbi.nlm.nih.gov/pubmed/26405604 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1036214 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|